[1]唐庆华,贡铁军,马军. 急性髓细胞白血病的治疗进展[J]. 循证医学,2022,22:80-83+94. [2]李姗姗,潘慧李,茗达.急性髓系白血病免疫治疗方式及研究进展[J]. 中国细胞生物学学报,2019,41:2393-2405. [3]Tamamyan G, Kadia T, Ravandi F, et al. Frontline treatment of acute myeloid leukemia in adults[J]. Critical Rev Oncol Hematol, 2017, 110: 20-34 [4]Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML[J]. Nat Rev Clin Oncol, 2021, 18:577-590. [5]颜志鹏,曾妮,吴頔,等.RNA结合蛋白PABPC1的功能及生物学作用[J]. 生物化学与生物物理进展,2019,46:545-554. [6]Sun LY, Wang WT, Han C, et al. The onco- micro-peptide APPLE promotes hematopoietic malignancy by enhancing translation initiation[J]. Molecular Cell, 2021, 81:4493-4508. [7]Malka-Mahieu H, Newman M, Désaubry L, et al. Molecular pathways: the eIF4F translation initiation complex-new opportunities for cancer treatment[J]. Clin Cancer Res, 2017, 23:21-25. [8]Barbieri I, Tzelepis K, Pandolfin L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control[J]. Nature, 2017, 552:126-131. [9]Romero D, New maintenance option for AML[J]. Nat Rev Clin Oncol, 2021, 18: 132.doi: 10.1038/s41571-021-00475-3. [10]Yankova E, Wesley B, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature, 2021, 593: 597-601. |